Korea signals,
read at source.
Selected market briefs from Nathan Research Group's Seoul desk, built from local filings, primary-source interviews, and operator context.
It ships more detectors every year — and earns less on each one.
Every year the world takes more X-ray images, and every year the panel that captures them sells for less. The merchant flat-panel-detector market is a textbook case of what one imaging-research house calls 'rising volumes, falling prices': unit demand compounds in the mid-single digits while the price of a detector erodes, and the value migrates up to the systems, software and AI wrapped around it. This is a study of that market — its commoditizing core, the faster machine-vision business detector makers run beside it, and the Chinese supply that is both its biggest demand engine and its sharpest margin threat — read through Korea's Vieworks, the one Korean merchant detector maker that stayed profitable while its peers went into the red.
Vieworks · Jun 17, 2026
→
Games & InteractiveA twenty-year-old game that won't stop paying — until it does.
Every year the world spends more on games, and every year a little less of that money flows to the genre Korea built its industry on. Korea's mobile-MMORPG market is in structural decline — its share of mobile-RPG revenue fell from 78.8 to 56.2 percent in four years as spending rotated to sub-culture and idle titles. Yet the two-decade-old trademarks underneath it keep paying: a legacy MMORPG IP does not decay, it re-platforms, resetting its revenue in a sawtooth with the richest royalties earned in China behind a political publishing gate. This is a study of that market, read through Korea's Webzen — the cohort's margin king, living off a single twenty-year-old trademark, MU.
Webzen · Jun 17, 2026
→
Semiconductors / OSATThe packaging boom went one way. It went the other.
Semiconductor back-end is in the middle of the largest value migration in its history: as AI and high-performance computing pull the money toward advanced packaging — 2.5D/3D, fan-out, chiplet integration — the OSAT industry is splitting into a fast, profitable frontier and a slow, commoditizing floor. This is a study of that split, read through Korea's LB Semicon, a pure-play in the one corner the migration bypassed: display-driver-IC packaging. It is the cleanest case of what the wrong side of a value migration looks like on a P&L — a recovering top line, a margin gone negative, a written-down fab, and a recapitalization to fund a pivot larger rivals reached years ago.
LB Semicon · Jun 17, 2026
→
Private EducationThe students are vanishing. The spending keeps breaking records.
Korea is losing its children. The school-age population has fallen by half from its peak, first-grade enrollment just dropped below 300,000 for the first time, and yet private-education spending set its fourth straight record in 2024 at KRW 29.2 trillion — up roughly 60 percent in a decade while the student count fell. This is a study of that paradox — a consumer market that grows as its customer base disappears, because a shrinking cohort competes harder for a fixed pool of elite university and medical seats, and each remaining student spends more — read through Korea's scale leader in after-school tutoring, Megastudy.
Megastudy · Jun 17, 2026
→
DermocosmeticsCheap to make, hard to copy: the derma corner of the K-beauty boom.
K-beauty is having its biggest year ever — Korea exported a record US$10.2bn of cosmetics in 2024 and became the largest source of beauty imports into the United States. But most of that boom is viral, low-moat, margin-thin. The defensible slice is dermocosmetics — clinical, skin-barrier, dermatologist-endorsed skincare that commands a price and a loyalty mass beauty cannot. This is a study of that derma corner of the export wave: how big the category is, why it earns the margin it does, and where it goes to 2030 — read through Korea's Neopharm, a specialist earning a ~22 percent operating margin in a field where broad beauty earns five.
Neopharm · Jun 17, 2026
→
PharmaceuticalsThe government cut the price. The market climbed the chain.
In March 2026 Korea cut the one thing a generic-centric drug market is built to fear: the price. The generic reimbursement ceiling falls from 53.55% to the low-40s% of the originator, compressing the slow, administered Rx core that has anchored Korean pharma — a ~US$14–30bn market the houses cannot even agree on the size of, growing somewhere between 2.4% and 9.2%. The structural fault line is where price escapes the regulator: at the aesthetics, export, CDMO and biopharma nodes, not the reimbursed one. This is a study of that market — its sizing band, its value chain and its rotation — through one mid-cap sterile-injectable maker, Korea's Huons, whose own merger filing names that exact reform as its reason to climb.
Huons · Jun 18, 2026
→Trusted by global institutions.
01Private Equity & Venture Capital
500+PE/VC engagements
02Hedge Funds & Asset Managers
50+Hedge fund clients
03Management Consultancies
Top 10Firms served
04Corporate Strategy Teams
200+Strategy projects
05Investment Banks
100+M&A engagements
From deal sourcing to post-acquisition value creation, access Korean industry experts who accelerate your due diligence and portfolio strategy.
Simple. Fast. Precise.
Four steps. One working week, at most. An ontology for moving from a research question to an answered one.
Define Your Inquiry
Share your research question or project scope. Our team clarifies objectives, timeline, and compliance requirements — so nothing is left to assumption.
Pinpoint the Right Expert
We identify and vet the most relevant Korean experts from our curated network — typically presenting qualified profiles within 24 hours.
Engage on Your Terms
Conduct expert calls, surveys, or workshops in your preferred format. We handle scheduling, compliance checks, and all logistics end-to-end.
Insights That Move You Forward
Receive actionable insights that advance your decision. Follow-up engagements and additional expert connections available on demand.
Share your expertise.
Shape global decisions.
Join Korea’s premier expert network and connect with the world’s leading investors, consultancies, and corporations seeking your knowledge.
- Competitive CompensationProfessional-grade consulting fees for your expertise.
- Full FlexibilityEvery engagement is voluntary, scheduled around you.
- Global ExposureWork with leading investors, consultancies, and corporates.
The Korean market moves fast. Stay ahead.
Curated deep dives and regulatory updates from Nathan Research Group.
We value your privacy
We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more